COVID-19 Clinical Trials in Houston

Showing 1-20 of 170 trials

Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients

NCT05101213

This phase I trial tests the feasibility and safety of genetically modified cytotoxic T-lymphocytes in controlling infections caused by adenovirus (ADV), BK virus (BKV), cytomegalovirus (CMV), JC virus (JCV), or COVID-19 in immunocompromised patients with cancer. Viral infections are a leading cause of morbidity and mortality after hematopoietic stem cell transplantation, and therapeutic options for these infections are often complicated by associated toxicities. Genetically modified cytotoxic T-lymphocytes (CTLs) are designed to kill a specific virus that can cause infections. Depending on which virus a patient is infected with (ADV, BKV, CMV, JCV, or COVID-19), the CTLs will be designed to specifically attack that virus. Giving genetically modified CTLs may help to control the infection.

Adenovirus InfectionBK Virus InfectionCytomegaloviral Infection+4 more

M.D. Anderson Cancer Center30 participantsStarted Jan 2023

Houston, Texas, United States

RECRUITINGPhase 1/2< 1 mile

Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment of Moderate, Severe or Critical Pneumonia

NCT04565665

This is a phase I trial followed by a phase II randomized trial. The purpose of phase I study is the feasibility of treating patients with acute respiratory distress syndrome (ARDS) related to COVID-19 infection (COVID-19) with cord blood-derived mesenchymal stem cells (MSC). The purpose of the phase II trial is to compare the effect of MSC with standard of care in these patients. MSCs are a type of stem cells that can be taken from umbilical cord blood and grown into many different cell types that can be used to treat cancer and other diseases. The MSCs being used for infusion in this trial are collected from healthy, unrelated donors and are stored and grown in a laboratory. Giving MSC infusions may help control the symptoms of COVID-19 related ARDS.

COVID-19 InfectionCOVID-19-Associated Acute Respiratory Distress SyndromeHematopoietic and Lymphoid Cell Neoplasm+2 more

M.D. Anderson Cancer Center70 participantsStarted Jul 2020

Houston, Texas, United States

Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients

Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment of Moderate, Severe or Critical Pneumonia

COVID-19 Trials in Other Cities

A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children

I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients

Study of VYD2311 for the Prevention of COVID-19

A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease

The Impact of COVID-19 on Pulmonary Procedures

A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That Are Considered at Higher Risk of Severe COVID-19

Assessment of the Psychosocial Impact of the COVID-19 Pandemic on the MD Anderson Cancer Center Workforce

Understanding the Long-term Impact of COVID on Children and Families

A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age

RECOVER-VITAL: Platform Protocol to Measure the Effects of Antiviral Therapies on Long COVID Symptoms

Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir)

Innovative Support for Patients With SARS-COV2 Infections (COVID-19) Registry (INSPIRE)

Safety and Immunogenicity Trial of MPV/S-2P SARS-CoV-2 Vaccine in Adults

Safety and Immunogenicity of NVX-CoV2705

Reparixin add-on Therapy to Standard Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia

Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID

Evaluation of COVID-19 and Flu A/B 3 in 1 Combo Rapid Test

ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19

Other Conditions in Houston